State of New Jersey Common Pension Fund D Sells 1,816 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

State of New Jersey Common Pension Fund D decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 3.7% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,361 shares of the biopharmaceutical company’s stock after selling 1,816 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Halozyme Therapeutics were worth $2,711,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in HALO. Congress Asset Management Co. increased its holdings in shares of Halozyme Therapeutics by 446.5% during the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock worth $139,298,000 after acquiring an additional 1,988,238 shares during the last quarter. Handelsbanken Fonder AB raised its position in shares of Halozyme Therapeutics by 76.9% in the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock valued at $112,715,000 after purchasing an additional 856,200 shares during the period. Boston Trust Walden Corp acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth about $23,211,000. Swedbank AB acquired a new stake in shares of Halozyme Therapeutics during the 1st quarter worth about $13,927,000. Finally, Epoch Investment Partners Inc. boosted its holdings in shares of Halozyme Therapeutics by 23.3% during the 1st quarter. Epoch Investment Partners Inc. now owns 1,433,612 shares of the biopharmaceutical company’s stock worth $58,319,000 after buying an additional 270,579 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $58.61 on Thursday. The company has a 50 day moving average of $56.46 and a 200-day moving average of $53.22. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 1-year low of $33.15 and a 1-year high of $65.53. The company has a market cap of $7.46 billion, a PE ratio of 19.41, a price-to-earnings-growth ratio of 0.55 and a beta of 1.29.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total value of $532,600.00. Following the transaction, the senior vice president now owns 173,756 shares in the company, valued at $9,254,244.56. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last quarter, insiders sold 70,000 shares of company stock valued at $4,042,500. Corporate insiders own 2.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. HC Wainwright raised their price objective on shares of Halozyme Therapeutics from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. JPMorgan Chase & Co. downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their price target for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. TD Cowen increased their price objective on Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Benchmark reissued a “buy” rating and set a $60.00 target price on shares of Halozyme Therapeutics in a report on Thursday, August 8th. Finally, Morgan Stanley raised their price target on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $61.11.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.